One of the strangest CCs on record. Arestvyr is already developed (outside of extending the shelf life and coming up with a pediatric version). The other programs are early stage. The company is going to exit early stage development and partner instead. This is not really an operating entity anymore. Arestvyr customers will materialize or not. SIGA does not need a big sales force. Arestvyr production is out sourced. What is the day to day business?
But they are firing the R&D staff BEFORE they have a partnership. What sense does that make? What happens if a partner does not materialize? Further SIGA's R&D people are probably best in the world on dengue and SIGA's other viruses. A partner probably wants these people or at least the option of taking them on board. Strange.